Myxoma viral serpin, Serp-1, a unique interceptor of coagulation and innate immune pathways

Summary

Serpins maintain haemostasis through regulation of serine proteinases in the thrombotic and thrombolytic pathways. Viruses encode serpins that can alter thrombotic and thrombolytic responses producing, in some cases, disseminated intravascular coagulation (DIC). However, it has not been precisely defined how viral serpins induce these profound responses. The rabbit myxoma viral serpin, Serp-1 inhibits urokinase- and tissue-type plasminogen activators (uPA and tPA), plasmin and factor Xa in vitro and exhibits remarkable anti-inflammatory activity in various animal models. The effects of Serp-1 on activation of human platelets, endothelial cells, monocytes and T cells that mediate thrombosis and innate immune responses were therefore examined. We found that Serp-1 attenuated platelet and mononuclear cell adhesion to fibronectin and collagen. Serp-1 similarly inhibited monocyte migration into the peritoneum. Serp-1 inhibition of monocyte migration was lost in uPA receptor (uPAR) deficient mice. Serp-1 bound to the plasma membrane surface and altered uPA activation of endothelial cells (p=0.001), thrombin activation of platelets (p=0.021) and phorbol ester activation of endothelial (p=0.047), monocyte (p=0.011) and Jurkat T cells (p=0.012) as measured by intracellular calcium. Modulation of cellular activation was confirmed by membrane fluidity analysis. Microarray analysis of Serp-1 treated endothelial cells revealed alterations in Inositol 1,4,5-triphosphate receptor type II (ITPR2) a calcium-regulating gene. This study demonstrates the unique capacity ofa viral serpin, Serp-1 to modify adhesion, activation, gene expression and calcium homeostasis in a wide range of cells that regulate coagulation and inflammation. Endothelial cells potentially represent a pivotal regulatory point for Serp-1 anti-inflammatory activity.

Keywords

Serpin - adhesion - calcium - membrane fluidity - ITPR2

• References

• 1 Tousoulis D. et al. Inflammatory and thrombotic mechanisms in coronary atherosclerosis. Heart 2003; 89: 993-7.
• 2 Esmon CT. Crosstalk between inflammation and thrombosis. Maturitas 2004; 47: 305-14.
• 3 Wagner DD, Burger PC. Platelets in inflammation and thrombosis. Arterioscler Thromb Vasc Biol 2003; 23: 2131-7.
• 4 Landmesser U. et al. Endothelial function –A critical determinant in atherosclerosis. Circulation 2004; 109: 27-33.
• 5 Pearson JD. Endothelial cell function and thrombosis. Baillie Clin Haematol 1999; 12: 329-41.
• 6 Douglas BC. et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998; 91: 3527-61.
• 7 Gibbins JM. Platelet adhesion signalling and the regulation of thrombus formation. J Cell Sci 2004; 117: 3415-25.
• 8 Shebuski RJ, Kilgore KS. Role of inflammatory mediators in thrombogenesis. J Pharmacol Exp Therap 2002; 300: 729-35.
• 9 Vallee I. et al. African swine fever virus infection of porcine aortic endothelial cells leads to inhibition of inflammatory responses, activation of the thrombotic state and apoptosis. J Virol 2001; 75: 10372-82.
• 10 Johnston JB, McFadden G. Poxvirus immunomodulatory strategies: Current perspectives. J Virol 2003; 77: 6093-100.
• 11 Summerfield A. et al. Pathogenesis of granulocytopenia and bone marrow atrophy during classical swine fever involves apoptosis and necrosis of uninfected cells. Virology 2000; 272: 50-60.
• 12 Richardson J. et al. Serpins, the vasculature, and viral therapeutics. Front Biosci 2006; 11: 1042-56.
• 13 Lucas A. et al. Virus-encoded serine proteinase inhibitor SERP-1 inhibits atherosclerotic plaque development after balloon angioplasty. Circulation 1996; 94: 2890-900.
• 14 Lucas A, McFadden G. Secreted immunomodulatory viral proteins as novel biotherapeutics. J Immunol 2004; 173: 4765-74.
• 15 Lucas A. et al. Transplant Vasculopathy: Viral antiinflammatory serpin regulation of atherogenesis. J Heart Lung Trans 2000; 19: 1029-38.
• 16 Dai E, Guan H, Liu L. et al. Serp-1, a viral anti-inflammatory serpin, regulates cellular serine proteinase and serpin responses to vascular injury. J Biol Chem 2003; 278: 18563-72.
• 17 Miller LW. et al. Inhibition of transplant vasculopathy in a rat aortic allograft model after infusion of anti-inflammatory viral serpin. Circulation 2000; 101: 1598-605.
• 18 Lomas DA. et al. Inhibition of plasmin, urokinase, tissue plasminogen activator, and CIS by a myxoma virus serine proteinase inhibitor. J Biol Chem 1993; 268: 516-21.
• 19 Nash P. et al. Inhibitory Specificity of the anti-inflammatory myxoma virus serpin, Serp-1. J Biol Chem 1998; 273: 20982-91.
• 20 Bootman MD. et al. Calcium signalling—an overview. Sem Cell Dev Biol 2001; 12: 3-10.
• 21 Galione A, Churchill GC. Interactions between calcium release pathways: multiple messengers and multiple stores. Cell Calcium 2002; 32: 343-54.
• 22 Mooren F, Kinne R. Cellular calcium in health and disease. Biochim Biophys Acta 1998; 1406: 127-51.
• 23 Hollan S. Membrane fluidity of blood cells. Haematolgia (Budap) 1996; 27: 109-27.
• 24 Helmreich EJM. Environmental influences on signal transduction through membranes: a retrospective mini-review. Biophys Chem 2003; 100: 519-34.
• 25 Caimi G. et al. Polymorphonuclear integrins, membrane fluidity and cytosolic calcium content after activation in essential hypertension. Hyperten 2000; 36: 813-7.
• 26 Zalai CV. et al. Increased circulating monocyte activation in patients with unstable caronary syndromes. J Amer Coll Cardiol 2001; 38: 1340-8.
• 27 Grynkiewicz G. et al. A new generation of Ca²⁺ indicators with greatly improved fluorescence properties. J Biol Chem 1985; 260: 3440-50.
• 28 Hancock WW. et al. Binding of activated protein C to a specific receptor on human mononuclear phagocytes inhibits intracellular calcium signaling and monocyte-dependent proliferative responses. Transplantation 1995; 60: 1525-32.
• 29 Balasubramanyam M, Gardner JP. Protein kinase C modulates cytosolic free calcium by stimulating calcium pump activity in jurkat T cells. Cell Calcium 1995; 18: 526-41.
• 30 Silverman GA. et al. The serpins are an expanding superfamily of structurally similar but functionally diverse proteins – evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J Biol Chem 2001; 276: 33293-6.
• 31 Parfyonova YV. et al. Plasminogen activators in vascular remodeling and angiogenesis. Biochemistry (Mosc) 2002; 67: 139-56.
• 32 Tan P. et al. Cellular and molecular mechanisms of inflammation and thrombosis. Eur J Vasc Endovasc Surg 1999; 17: 373-89.
• 33 Strukova SM. Role of platelets and serine proteinases in coupling of blood coagulation and inflammation. Biochemistry (Mosc) 2004; 69: 1067-81.
• 34 Seet BT. et al. Poxviruses and immune evasion. Annu Rev Immunol 2003; 21: 377-423.
• 35 Ruggeri ZM. Platelets in atherothrombosis. Nat Med 2002; 08: 1227-34.
• 36 Kiss Z. Effects of phorbol ester on phospholipid metabolism. Prog Lipid Res 1990; 29: 141-66.
• 37 Liu J. et al. Noncatalytic domain of uPA stimulates human extravillous trophoblast migration by using phospholipase C, phosphatidylinositol 3-kinase and mitogen-activated protein kinase. Exp Cell Res 2003; 286: 138-51.
• 38 Sherbet GV. Calcium signalling in Cancer. New York: CRC Press; 2001
• 39 Tiruppathi C. et al. Role of Ca²⁺ signaling in the regulation of endothelial permeability. Vasc Pharmacol 2003; 39: 173-85.
• 40 Patterson RL. et al. Inositol 1,4,5-triphosphate receptors as signal integrators. Ann Rev Biochem 2004; 73: 437-65.
• 41 Missiaen L. et al. Abnormal intracellular Ca²⁺ homeostasis and disease. Cell Calcium 2000; 28: 1-21.
• 42 Marcondes S. et al. Platelets induce human umblical vein endothelial cell proliferation through P-selectin. Life Sci 2000; 66: 1817-26.
• 43 Ross R. Atherosclerosis – An inflammatory disease. New Eng J Med 1999; 340: 115-26.
• 44 Libby P. Vascular biology of atherosclerosis: Overview and state of the art. Am J Cardiol 2003; 91: 3A-6A.